Jade Biosciences is a clinical-stage biopharmaceutical company developing biologic therapies for autoimmune diseases. Its lead product candidate, JADE101, is a monoclonal antibody targeting APRIL for the treatment of IgA nephropathy. The company’s second candidate, JADE201, is a monoclonal antibody targeting BAFF-R for multiple autoimmune disorders, including rheumatoid arthritis. A third candidate, JADE301, targets an undisclosed pathway and is in preclinical development. Jade Biosciences licenses discovery-stage assets from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. The company plans to initiate Phase 1 clinical trials for JADE201 and JADE301 in 2026 and 2027, respectively, and is evaluating JADE101 for other autoimmune conditions.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage jadebiosciences.com
Sector Healthcare IR page jadebiosciences.com/investors
Tags
autoimmune diseases, monoclonal antibodies, iga nephropathy, rheumatoid arthritis, april, baff-r, half-life extension, clinical-stage, JADE101, JADE201, JADE301, Paragon Therapeutics, Fairmount
Press page jadebiosciences.com/investors/news

Metrics

Valuation  
Market cap $ 942.479M
Market cap (USD) $ 942.479M
P/E -7.55
PEG —
P/BV 2.07
P/S —
P/OCF -8.27
P/FCF -9.93
Dividend yield —
Turnover / mcap —
Returns  
ROE -38.3%
ROI -52.0%
ROIC -34.8%
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 30
Quality score -77.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025
Assets 349.781M
Net profit -127.41M
Free cash flow -94.885M

Figure FY 2025
Share price 15.43
P/FCF -8.02

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 574,000 1.09M 675,000 417,000 724,000
Cash and deposits (USD) 3.51M 4.57M 54.2M 22.4M 23.5M 33.8M 88.4M
Right-of-use assets (USD) — — 542,000 1M 614,000 209,000 726,000
Cash flow detail
Operating cash flow (USD) — -7.86M -27.4M -39.1M -56.8M -71.2M -94.7M
Purchases of property, plant and equipment (USD) — — -181,000 -195,000 -142,000 — -196,000
Change in payables (cash effect) (USD) — 37,000 609,000 1.37M -164,000 -2.17M 361,000
Share-based compensation (USD) — 58,000 2.04M 5.48M 11.9M 11.3M 20M
Free cash flow (OCF - PPE - intangibles) (USD) — — -27.6M -39.3M -56.9M — -94.9M
Income detail
Research and development expense (USD) — 7.94M 15M 38.6M 64.2M 53.2M 93.1M
↳ 5y CAGR +63.6%
Total comprehensive income (USD) — -9.61M -23M -51.9M -74.8M -69.8M -127M
Comprehensive income to owners (USD) — -9.61M -23M -51.9M -74.8M -69.8M -127M
Reported Aug 16, 2021 Mar 30, 2022 Mar 30, 2022 Mar 29, 2023 Mar 25, 2024 Mar 27, 2025 Mar 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

• JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026

• JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027

• JADE201 Phase 1 clinical trial in rheumatoid arthritis ongoing; interim data expected in 2027

• JADE301 Phase 1 clinical trial in dermatomyositis expected to initiate in the fourth quarter of 2026, with interim data expected in the second half of 2027

• Cash, cash equivalents, and investments of $476 million as of September 30, 2026 expected to provide runway into the fourth quarter of 2028

San Francisco and Vancouver, British Columbia – November 13, 2026 – Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the third quarter ending September 30, 2026, and provided a corporate update.

Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Show more

NecessaryAlways Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

Uncategorised

Other uncategorised cookies are those that are being analysed and have not been classified into a category as yet.

Accept All Save My Preferences Reject All

Powered by

Skip to content

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:

  • Guggenheim 3rd Annual Healthcare Innovation Conference Fireside Chat: Tuesday, November 10, 2026 at 3:00 p.m. ET Location: Boston, MA

  • Stifel Healthcare Conference Fireside Chat: Wednesday, November 11, 2026 at 10:00 a.m. ET Location: New York, NY

  • UBS Global Biopharma Conference Fireside Chat: Monday, November 16, 2026 at 12:00 p.m. GMT Location: London, UK

  • Jefferies Global Healthcare ConferenceFireside Chat: Tuesday, November 17, 2026 at 10:30 a.m. GMT Location: London, UK

Members of the Jade management team will host one-on-one investor meetings during the conferences.

A live webcast of each of the fireside chats will be available on the Events page of the Jade Biosciences website, with an archived replay accessible for 90 days following the event.

About Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-β monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.

Jade Biosciences Contact

Zane Goodwin [email protected] [email protected]

Primary Logo

Notifications

October 21, 2026

  • EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026

  • JUNIPER Phase 2 Trial-in-Progress poster highlights ongoing study of JADE101 in IgA nephropathy; interim data now expected in the second quarter of 2027

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 21, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that three posters related to JADE101, a novel, ultra-high affinity and half-life extended investigational anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody in development for the treatment of immunoglobulin A nephropathy (IgAN), will be presented at the American Society of Nephrology (ASN) Kidney Week 2026, being held in Denver, Colorado from October 21-25, 2026. The presentations highlight both the scientific foundation and continued clinical advancement of the JADE101 program in IgAN, including the planned acceleration of the EVERGREEN Phase 3 clinical trial, with initiation now expected in the fourth quarter of 2026.

“The anticipated initiation of EVERGREEN ahead of schedule reflects the disciplined execution of an experienced team to efficiently advance the JADE101 IgA nephropathy program into Phase 3 development,” said Andrew King, Ph.D., President, Research & Development of Jade Biosciences. “The presentations at ASN add to the growing body of evidence that has strengthened our conviction in JADE101’s potential best-in-class profile, characterized by potent, rapid and deep IgA reductions predicted to be sustained with convenient quarterly dosing.”

Jade’s presentations at Kidney Week 2026 include Trial-in-Progress posters for the upcoming EVERGREEN Phase 3 clinical trial and the ongoing JUNIPER Phase 2 clinical trial. Jade now expects to report interim data from JUNIPER in the second quarter of 2027. In addition, Jade will be presenting a model-based assessment poster featuring analyses integrating clinical and biomarker data to inform dose selection, characterize anticipated responses to APRIL inhibition, and support the accelerated development of JADE101.

Poster Presentations at ASN Kidney Week 2026

Title: Model-Based Assessment of Clinical Responses to A Proliferation-Inducing Ligand (APRIL) Blockade Informing Development of the Anti-APRIL Monoclonal Antibody JADE101 in IgAN

Session: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

Poster Number: TH-PO0822

Date / Time: October 22, 2026, from 10:00 AM to 12:00 p.m. MT

Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Jade101 in Participants with IgAN

Session: Informational Posters

Poster Number: INFO13-SA

Date / Time: October 24, 2026, from 10:00 AM to 12:00 p.m. MT

Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Jade101 Administered Subcutaneously in Participants with Immunoglobulin A Nephropathy

Session: Informational Posters

Poster Number: INFO14-SA

Date / Time: October 24, 2026, from 10:00 AM to 12:00 p.m. MT

The posters will be available on the Publications section of Jade’s website following their presentations.

Prompts

Jade Biosciences, Inc. (ticker JBIO), listed in United States.

Company History

Date Change Detail
Feb 18, 2025 Renamed AEROVATE THERAPEUTICS, INC. → JADE BIOSCIENCES, INC.
— Former tickers AVTE

ETFs Holding Jade Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
FMED 0.31% 7,426 $ 158.619K Aug 31, 2026
SCDS 0.16% 962 $ 14.815K Nov 17, 2026
FFSM 0.12% 93,021 $ 1.837M Jul 31, 2026
VFMO 0.12% 110,165 $ 2.353M Aug 31, 2026
RESM 0.03% 57 $ 1,266.54 Jun 30, 2026
AVSC 0.01% 25,087 $ 384.709K Nov 16, 2026
MSSM 0.01% 3,226 $ 68.907K Aug 31, 2026
AVUS 0.00% 1,682 $ 25.793K Nov 16, 2026